Menstrual blood-derived stem cells
Human menstrual fluid stem cells.
General information
Menstrual blood-derived stem cells (MenSCs) are isolated from human menstrual fluid. The cells express canonical mesenchymal stem cell markers and do not express hematopoietic stem cell markers. MenSCs can differentiate into adipocytes, osteocytes or chondrocytes under proper conditions. They actively involved in paracrine signalling and have immunomodulatory properties (Chen et al., 2019a). Inherent properties of MenSCs make them an object of research interest in the field of regenerative medicine. Their clinical potential has been addressed in the case of various health conditions including acute lung injury, Alzheimer’s disease, Asherman syndrome, cutaneous wound, diabetes, Duchenne muscular dystrophy, endometriosis, liver disease, myocardial infarction, neurodegenerative diseases, ovarian-related disease, or stroke (Chen et al., 2019b).
Synonyms
MenSCs; endometrial regenerative cells; menstrual blood stem cells
Supporting references
Link | Tested on | Impact factor | Notes | Publication date |
---|---|---|---|---|
Human menstrual blood-derived stem cells as immunoregulatory therapy in COVID-19: A case report and review of the literature
Stem cells Cell-based therapy Case report Mixed substance |
A patient | 1.34 | Clinical improvement observed after treatment in the case of a patient with severe pulmonary injury caused by COVID-19. Sample size: 1. |
Mar/06/2021 |
AI-suggested references
Link | Publication date |
---|---|
Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & II
|
Mar/07/2022 |
Clinical trials
ID | Title | Status | Phase | Start date | Completion date |
---|---|---|---|---|---|
NCT05019287 | Menstrual Blood Stem Cells in Severe Covid-19 | Completed | Phase 1|Phase 2 | Apr/17/2021 | Jun/09/2021 |
|